Guggenheim Maintains Buy on Jade Biosciences, Raises Price Target to $32

Benzinga Newsdesk www.benzinga.com Positive 77.6%

Neg 0% Neu 0% Pos 77.6%

Guggenheim analyst Vamil Divan maintains Jade Biosciences (NASDAQ:JBIO) with a Buy and raises the price target from $23 to $32.